Trial Profile
A 32-week Randomised, Multinational, Treat-to-target, Open Label, Parallel Group Comparison of Stepwise Insulin Intensification of Biphasic Insulin Aspart (BIAsp) 30 and Basal-bolus Therapy With Insulin Glargine and Insulin Aspart in Insulin naïve Type 2 Diabetic Patients Inadequately Controlled on Oral Anti-diabetic Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary) ; Insulin aspart; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 01 Feb 2018 Primary endpoint (Change in HbA1c (glycosylated haemoglobin)) has not been met as per the results published in the Diabetes Therapy.
- 01 Feb 2018 Results published in the Diabetes Therapy
- 29 Sep 2016 Status changed from active, no longer recruiting to completed.